ArticleMolecular cancer2009
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Ymera Pignochino et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
92 papers cite itlatest 60 shown
this paperpooled ittrialcites it